Clinical trial
Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer…
NCT00126789 · ZARS Pharma Inc., Industry · Terminated
Key facts
| NCT number | NCT00126789 |
|---|---|
| Title | Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain |
| Official title | An Open-Label, Long-Term Safety Study to Evaluate the Safety of the ZR-02-01 Matrix Transdermal Fentanyl Patch for the Treatment of Moderate to Severe Cancer Pain |
| Lead sponsor | ZARS Pharma Inc., Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pain, Cancer |
| Intervention type | Drug |
| Interventions | Fentanyl Transdermal Matrix Patch ZR-02-01 |
| Enrollment | 24 |
| Start date | Aug 1, 2005 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Aug 4, 2005 |
| Last update posted | Jun 5, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: